Hospira Recalls Two Lots of Naloxone Hydrochloride

Hospira Recalls Two Lots of Naloxone Hydrochloride

Hospira, Inc., a Pfizer company, is voluntarily recalling lots 72680LL and 76510LL of naloxone hydrochloride injection at the hospital/institution level due to the potential presence of embedded and loose particulate matter on the syringe plunger. 

Naloxone is an opioid antagonist used to reverse opioid overdose, acting as a life-saving agent in emergency situations when a patient faces respiratory depression. 

In the event that loose particulates were administered to a patient from these recalled products, there is a likelihood the patient could experience adverse events ranging from local irritation, allergic reactions, phlebitis, end-organ granuloma, tissue ischemia, pulmonary emboli, pulmonary dysfunction, pulmonary infarction, and toxicity.

To date, Hospira, Inc. has not received reports of any adverse events associated with this issue for these lots. For further information, read the FDA’s recall alert.